A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, 24-week Study Investigating the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Moderate to Severe Rotator Cuff Tendinopathy and Failure to Conventional Therapy
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Tendinitis
- Focus Registrational; Therapeutic Use
- Acronyms UnchAIN
- Sponsors Novartis Pharma; Novartis Pharmaceuticals
Most Recent Events
- 23 Dec 2024 Status changed from active, no longer recruiting to completed.
- 06 Aug 2024 Planned End Date changed from 30 Apr 2025 to 27 Dec 2024.
- 06 Aug 2024 Planned primary completion date changed from 30 Apr 2025 to 27 Dec 2024.